JPWO2021032643A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021032643A5
JPWO2021032643A5 JP2022510087A JP2022510087A JPWO2021032643A5 JP WO2021032643 A5 JPWO2021032643 A5 JP WO2021032643A5 JP 2022510087 A JP2022510087 A JP 2022510087A JP 2022510087 A JP2022510087 A JP 2022510087A JP WO2021032643 A5 JPWO2021032643 A5 JP WO2021032643A5
Authority
JP
Japan
Prior art keywords
group
methyl
hydrogen
oxo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022510087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544803A (ja
JP2022544803A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/072911 external-priority patent/WO2021032643A1/en
Publication of JP2022544803A publication Critical patent/JP2022544803A/ja
Publication of JP2022544803A5 publication Critical patent/JP2022544803A5/ja
Publication of JPWO2021032643A5 publication Critical patent/JPWO2021032643A5/ja
Pending legal-status Critical Current

Links

JP2022510087A 2019-08-16 2020-08-14 筋肉消耗及び他の状態の治療及び予防に好適な化合物 Pending JP2022544803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19192107.1 2019-08-16
EP19192107 2019-08-16
PCT/EP2020/072911 WO2021032643A1 (en) 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions

Publications (3)

Publication Number Publication Date
JP2022544803A JP2022544803A (ja) 2022-10-21
JP2022544803A5 JP2022544803A5 (https=) 2023-08-17
JPWO2021032643A5 true JPWO2021032643A5 (https=) 2023-08-17

Family

ID=67659191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510087A Pending JP2022544803A (ja) 2019-08-16 2020-08-14 筋肉消耗及び他の状態の治療及び予防に好適な化合物

Country Status (13)

Country Link
US (1) US12331042B2 (https=)
EP (1) EP4013497B1 (https=)
JP (1) JP2022544803A (https=)
KR (1) KR20220047807A (https=)
CN (1) CN114302881B (https=)
AU (1) AU2020334194A1 (https=)
BR (1) BR112022002769A2 (https=)
CA (1) CA3144700A1 (https=)
CL (1) CL2022000320A1 (https=)
IL (1) IL290540A (https=)
MX (1) MX2022002022A (https=)
WO (1) WO2021032643A1 (https=)
ZA (1) ZA202202863B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102823820B1 (ko) * 2022-09-01 2025-06-23 단국대학교 천안캠퍼스 산학협력단 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물
AU2023348158A1 (en) * 2022-09-30 2025-02-27 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624524C (en) * 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
EP2072528A1 (en) 2007-12-19 2009-06-24 Labeit, Mr. Siegfried A host cell deficient for MuRF1 and MuRF2
WO2012154213A1 (en) * 2011-04-07 2012-11-15 Cornell University Cofluorons and methods of making and using them
AU2012268036B2 (en) * 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
CN112274183A (zh) * 2020-11-02 2021-01-29 李云莹 一种神经内科用脑部超声波治疗装置

Similar Documents

Publication Publication Date Title
RU2494095C2 (ru) Модифицированные миметики лизина
TWI280876B (en) Therapeutic drug for diabetes
JP2019094345A5 (https=)
JP2021516240A5 (https=)
TW200410671A (en) Medicines for inhibiting the activation of AP-1
JP2012529486A5 (https=)
JP2012527475A5 (https=)
CN107001806B (zh) 用于治疗心肺疾病的鞘氨醇-1-磷酸盐受体调节剂
JP2007527919A5 (https=)
JP2021529185A5 (https=)
JPWO2023195529A5 (https=)
JP2006520808A5 (https=)
JP2016519106A5 (https=)
JP2010248215A (ja) 筋弛緩促進剤及び筋弛緩不全等の筋組織に係る疾病の治療薬
JP2016514141A5 (https=)
JP2010527985A5 (https=)
JP2020111571A5 (https=)
JP2016522196A5 (https=)
RU2008119994A (ru) Ингибиторы калиевых каналов
RU2007101238A (ru) Пептидные агонисты вазопрессинового рецептора
JPWO2021032643A5 (https=)
JP2008519783A5 (https=)
JPWO2022198196A5 (https=)
CN114302881A (zh) 适用于治疗和预防肌肉萎缩和其他状况的化合物
JP2008528704A5 (https=)